What medication is used for pelvic inflammatory disease

What medication is used for pelvic inflammatory disease

As soon as pelvic inflammatory disease (PID) has been diagnosed, it needs to be treated with antibiotics. Two or more types of antibiotics may be taken at the same time. This ensures that all the bacteria are killed. It's very important to take all of your medicine as prescribed, or the infection may not go away.

For mild cases

Mild cases of PID can be treated at home. Antibiotic pills will likely be prescribed. You may also get an injection of antibiotics.

For more serious cases

Severe cases of PID need to be treated in the hospital. There, you will get antibiotics through an IV (intravenous) line. Your health will be closely watched. The length of your hospital stay depends on how sick you are. After you leave the hospital, antibiotic pills will likely be prescribed. If complications have occurred, you may need surgery to help treat them.

Make sure your partner gets treated

The bacteria that cause PID can also have harmful effects in men. Any partner you have had sex with in the past 60 days should be treated for chlamydia and gonorrhea. Your partner must be treated with antibiotics as well.

During treatment

Follow all your healthcare provider’s instructions. This will help you heal. During treatment:

  • Finish all of your antibiotics, even if you start to feel better. Otherwise, the infection might not go away. It could even get worse and become harder to treat.

  • Don’t have sex until both you and your partner have finished all of your antibiotics.

  • Relieve pelvic pain with a heating pad, hot water bottle, or ice pack. Your healthcare provider may also suggest a prescription or over-the-counter pain medicine.

  • Ask your healthcare provider if you should avoid alcohol, which can react with some antibiotics.

If you take birth control pills

When both you and your partner have finished your antibiotics, it’s OK to have sex. Use latex condoms to prevent future infections. Also, keep taking your birth control pills on schedule. Remember: Birth control pills help prevent pregnancy, but do not protect against sexually transmitted infections (STIs).

If the infection returns

Even after treatment, PID can come back. This could happen if you’re infected by another STI. But be aware that once you’ve had PID, bacteria that are normally harmless may be more likely to infect your upper genital tract. This means you could get PID again even without getting another STI. With each PID infection, the chances of complications go up.

When to call your healthcare provider

While you’re being treated for PID, call your healthcare provider if you have any of the following:

  • A fever of 100.4°F (38°C) or higher, or as directed by your healthcare provider

  • Worsening pelvic pain

  • Vomiting

  • A rash

  • Severe diarrhea

Medication Summary

Treatment of pelvic inflammatory disease (PID) should include empirical broad-spectrum antibiotics to cover the full complement of common causes. Antibiotics chosen should be effective against Chlamydia trachomatis and Neisseria gonorrhoeae, as well as against gram-negative facultative organisms, anaerobes, and streptococci. The Centers for Disease Control and Prevention (CDC) has outlined antibiotic regimens for outpatient and inpatient treatment of PID.

Macrolides

Class Summary

Macrolides are a class of antibiotics discovered in the bacterium Streptomyces. These agents are characterized by molecules made up of large-ring lactones. Many macrolides inhibit protein biosynthesis.

Azithromycin (Zithromax, Zmax)

  • View full drug information

Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected. This drug concentrates in phagocytes and fibroblasts, as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.

Azithromycin is used to treat mild-to-moderate microbial infections. Plasma concentrations are very low, but tissue concentrations are much higher, giving the drug value in treating intracellular organisms. Azithromycin has a long tissue half-life. Azithromycin is related to erythromycin. It is considered by many to be treatment of choice for C trachomatis genitourinary infection because it may be administered as a single dose, which improves adherence to treatment.

Cephalosporins, 3rd Generation

Class Summary

Cephalosporins are a group of broad-spectrum, semisynthetic beta-lactam antibiotics that are derived from the mold Cephalosporium (now termed Acremonium). They interfere with bacterial cell wall synthesis. Cephalosporin N and C are chemically related to penicillins, and cephalosporin P resembles fusidic acid.

Cephalosporins are grouped into generations according to their spectrum of antimicrobial activity. Third-generation cephalosporins are less active against gram-positive organisms then first-generation cephalosporins are. They are highly active against Enterobacteriaceae, Neisseria, and Haemophilus influenzae.

Ceftriaxone (Rocephin)

  • View full drug information

Cephalosporins are a group of broad-spectrum, semisynthetic beta-lactam antibiotics that are derived from the mold Cephalosporium (now termed Acremonium). They interfere with bacterial cell wall synthesis. Cephalosporin N and C are chemically related to penicillins, and cephalosporin P resembles fusidic acid.

Cephalosporins are grouped into generations according to their spectrum of antimicrobial activity. Third-generation cephalosporins are less active against gram-positive organisms then first-generation cephalosporins are. They are highly active against Enterobacteriaceae, Neisseria, and Haemophilus influenzae.

Cefotaxime (Claforan)

Cefotaxime is a third-generation cephalosporin with a broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. It arrests bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins, thereby in turn inhibiting bacterial growth. Cefotaxime is used to treat bloodstream infection and gynecologic infections caused by susceptible organisms.

Ceftizoxime (Cefizox)

  • View full drug information

Ceftizoxime is a third-generation cephalosporin with broad-spectrum gram-negative activity. It has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. It arrests bacterial growth by binding to 1 or more penicillin-binding proteins. Its gram-negative spectrum includes Moraxella catarrhalis. Dose selection depends on the severity of the infection and the susceptibility of the organism.

Cephalosporins, 2nd Generation

Class Summary

Cephalosporins are a group of broad-spectrum, semisynthetic beta-lactam antibiotics that are derived from the mold Cephalosporium (now termed Acremonium). They interfere with bacterial cell wall synthesis. Cephalosporin N and C are chemically related to penicillins, and cephalosporin P resembles fusidic acid.

Cephalosporins are grouped into generations according to their spectrum of antimicrobial activity. Compared with first-generation cephalosporins, second-generation agents have increased activity against gram-negative bacteria and decreased activity against gram-positive bacteria.

Cefoxitin (Mefoxin)

  • View full drug information

Cefoxitin is a second-generation cephalosporin indicated for infections with gram-positive cocci and gram-negative rods. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin.

Cefotetan (Cefotan)

  • View full drug information

Cefotetan is a second-generation cephalosporin indicated for infections caused by susceptible gram-positive cocci and gram-negative rods. The dose and route of administration depend on the condition of the patient, the severity of infection, and the susceptibility of the causative organism.

Tetracyclines

Class Summary

Tetracyclines are bacteriostatic broad-spectrum antibiotics derived from cultures of Streptomyces bacteria; they inhibit protein synthesis in susceptible organisms. These agents work by reversibly binding to the 30S ribosome of the microbial RNA and preventing the attachment of aminoacyl-tRNA with the acceptor site on the 70S ribosome.

Doxycycline (Vibramycin)

  • View full drug information

Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Antibiotics, Other

Class Summary

Lincosamide antibiotics (eg, clindamycin) inhibit protein synthesis. Imidazole antibiotics (eg, metronidazole) arrest RNA-dependent protein synthesis.

Clindamycin (Cleocin)

Clindamycin is a lincosamide used for treatment of serious skin and soft tissue staphylococcal infections. It is also effective against aerobic and anaerobic streptococci (except enterococci). It inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Metronidazole (Flagyl)

  • View full drug information

An imidazole ring–based antibiotic active against various anaerobic bacteria and protozoa, metronidazole is used in combination with other antimicrobial agents (except for treatment of Clostridium difficile enterocolitis).

Aminoglycosides

Class Summary

Aminoglycosides are a group of injectable bactericidal antibiotics that act by inhibiting bacterial protein synthesis. All aminoglycosides share the potential for ototoxicity and nephrotoxicity.

Gentamicin (Garamycin)

  • View full drug information

Gentamicin is an aminoglycoside antibiotic that provides gram-negative coverage. It is used in combination with an agent that is effective against gram-positive organisms and one that covers anaerobes. Dosing regimens are numerous. Adjust dose on the basis of creatinine clearance and changes in volume of distribution. Measure at least a trough level, drawn on the third or fourth dose (0.5 hours before dosing); a peak level may be drawn 0.5 hours after a 30-minute infusion.

Penicillins, Amino

Class Summary

An acid-stable semisynthetic penicillin, ampicillin has a broader spectrum of antimicrobial action than penicillin G does. It inhibits the growth of gram-positive and gram-negative bacteria. It is not resistant to penicillinase, but when it is combined with the beta-lactamase inhibitor sulbactam, the spectrum of activity is increased.

Ampicillin-sulbactam (Unasyn)

  • View full drug information

This formulation combines ampicillin with a beta-lactamase inhibitor. It interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms.

Uricosuric Agents

Class Summary

Uricosuric agents are used to increase serum concentrations of certain antibiotics and other drugs.

Probenecid

  • View full drug information

Probenecid inhibits tubular secretion of penicillin and usually increases penicillin plasma levels, regardless of the route of penicillin administration. It is used as an adjuvant to therapy with penicillin, ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin. A 2- to 4-fold elevation of penicillin plasma levels is demonstrated.

  1. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012 Jul. 120(1):37-43. [QxMD MEDLINE Link].

  2. Rivlin ME, Hunt JA. Ruptured tuboovarian abscess. Is hysterectomy necessary?. Obstet Gynecol. 1977 Nov. 50 (5):518-22. [QxMD MEDLINE Link].

  3. Laohaburanakit P, Treevijitsilp P, Tantawichian T, Bunyavejchevin S. Ruptured tuboovarian abscess in late pregnancy. A case report. J Reprod Med. 1999 Jun. 44 (6):551-5. [QxMD MEDLINE Link].

  4. De Temmerman G, Villeirs GM, Verstraete KL. Ruptured tuboovarian abscess causing peritonitis in a postmenopausal woman. A difficult diagnosis on imaging. JBR-BTR. 2003 Mar-Apr. 86 (2):72-3. [QxMD MEDLINE Link].

  5. Powers K, Lazarou G, Greston WM, Mikhail M. Rupture of a tuboovarian abscess into the anterior abdominal wall: a case report. J Reprod Med. 2007 Mar. 52 (3):235-7. [QxMD MEDLINE Link].

  6. [Guideline] Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23. 70 (4):1-187. [QxMD MEDLINE Link]. [Full Text].

  7. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012 Sep. 30 (7):1114-7. [QxMD MEDLINE Link].

  8. Patton DL, Wolner-Hanssen P, Zeng W, Lampe M, Wong K, Stamm WE, et al. The role of spermatozoa in the pathogenesis of Chlamydia trachomatis salpingitis in a primate model. Sex Transm Dis. 1993 Jul-Aug. 20(4):214-9. [QxMD MEDLINE Link].

  9. Paavonen J. Chlamydia trachomatis infections of the female genital tract: state of the art. Ann Med. 2012 Feb. 44(1):18-28. [QxMD MEDLINE Link].

  10. Taylor BD, Darville T, Ferrell RE, Kammerer CM, Ness RB, Haggerty CL. Variants in toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease. J Infect Dis. 2012 Feb 15. 205(4):603-9. [QxMD MEDLINE Link]. [Full Text].

  11. den Hartog JE, Ouburg S, Land JA, et al. Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated tubal pathology in subfertile women?. BMC Infect Dis. Jul 21 2006. 6:122.

  12. [Guideline] Royal College of Obstetricians and Gynaecologists (RCOG). Management of acute pelvic inflammatory disease. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG).; 2008 Nov. [Full Text].

  13. Herzog SA, Althaus CL, Heijne JC, Oakeshott P, Kerry S, Hay P, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. BMC Infect Dis. 2012 Aug 11. 12:187. [QxMD MEDLINE Link]. [Full Text].

  14. Hillis SD, Wasserheit JN. Screening for chlamydia--a key to the prevention of pelvic inflammatory disease. N Engl J Med. 1996 May 23. 334(21):1399-401. [QxMD MEDLINE Link].

  15. Hook EW, Handsfield HH. Gonococcal infections in the adult. Holmes KK, Sparling PF, Stamm WE, et al. eds. Sexually Transmitted Diseases. 4th edition. New York: McGraw Hill, Inc; 2008. 627-645.

  16. Mylonas I. Female genital Chlamydia trachomatis infection: where are we heading?. Arch Gynecol Obstet. 2012 May. 285(5):1271-85. [QxMD MEDLINE Link].

  17. Ross JD. Is Mycoplasma genitalium a cause of pelvic inflammatory disease?. Infect Dis Clin North Am. 2005 Jun. 19(2):407-13. [QxMD MEDLINE Link].

  18. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol. 2012 Jun. 206(6):476.e1-8. [QxMD MEDLINE Link].

  19. Bravender T, Matson SC. Adolescents, IUDs, PID, and Enterococcus: a report of two cases. J Pediatr Adolesc Gynecol. 2012 Jun. 25(3):e73-4. [QxMD MEDLINE Link].

  20. Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004 Oct. 104 (4):761-9. [QxMD MEDLINE Link].

  21. Avan BI, Fatmi Z, Rashid S. Comparison of clinical and laparascopic features of infertile women suffering from genital tuberculosis (TB) or pelvic inflammatory disease (PID) or endometriosis. J Pak Med Assoc. 2001 Nov. 51(11):393-9. [QxMD MEDLINE Link].

  22. Cherpes TL, Wiesenfeld HC, Melan MA, Kent JA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2006. 33:747-52.

  23. Jarvis GA, Chang TL. Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr HIV Res. 2012 Apr. 10(3):211-7. [QxMD MEDLINE Link].

  24. Brunham RC, Kimani J, Bwayo J, Maitha G, Maclean I, Yang C, et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis. 1996 Apr. 173(4):950-6. [QxMD MEDLINE Link].

  25. Bjartling C, Osser S, Johnsson A, Persson K. Clinical manifestations and epidemiology of the new genetic variant of Chlamydia trachomatis. Sex Transm Dis. 2009 Sep. 36(9):529-35. [QxMD MEDLINE Link].

  26. Kinnunen A, Molander P, Morrison R, Lehtinen M, Karttunen R, Tiitinen A, et al. Chlamydial heat shock protein 60--specific T cells in inflamed salpingeal tissue. Fertil Steril. 2002 Jan. 77(1):162-6. [QxMD MEDLINE Link].

  27. Makepeace BL, Watt PJ, Heckels JE, Christodoulides M. Interactions of Neisseria gonorrhoeae with mature human macrophage opacity proteins influence production of proinflammatory cytokines. Infect Immun. 2001 Mar. 69(3):1909-13. [QxMD MEDLINE Link]. [Full Text].

  28. Haggerty CL, Totten PA, Tang G, Astete SG, Ferris MJ, Norori J, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016 Sep. 92 (6):441-6. [QxMD MEDLINE Link].

  29. Baltic S. Novel Microbes Associated With Pelvic Inflammatory Disease, Infertility. Reuters Health Information. Available at http://www.medscape.com/viewarticle/859843. March 4, 2016; Accessed: January 9, 2017.

  30. Champion JD, Piper J, Shain RN, Perdue ST, Newton ER. Minority women with sexually transmitted diseases: sexual abuse and risk for pelvic inflammatory disease. Res Nurs Health. 2001 Feb. 24(1):38-43. [QxMD MEDLINE Link].

  31. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis. 2001 Apr. 28(4):240-5. [QxMD MEDLINE Link].

  32. Ness RB, Hillier SL, Kip KE, Richter HE, Soper DE, Stamm CA, et al. Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol. 2005 Jan 15. 161(2):186-95. [QxMD MEDLINE Link].

  33. Koumans EH, Kendrick JS. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis. 2001 May. 28(5):292-7. [QxMD MEDLINE Link].

  34. Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004 Oct. 104(4):761-9. [QxMD MEDLINE Link].

  35. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol. 2001 Jul. 185(1):121-7. [QxMD MEDLINE Link].

  36. Shelton JD. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet. 2001 Feb 10. 357(9254):443. [QxMD MEDLINE Link].

  37. [Guideline] CDC, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006. 55(RR-11):1-94.

  38. Kelly EK, Rudinsky SW. Intrauterine contraception: current evidence-based recommendations. J Midwifery Womens Health. 2007 Sep-Oct. 52(5):505-7. [QxMD MEDLINE Link].

  39. Meirik O. Intrauterine devices - upper and lower genital tract infections. Contraception. 2007. 06;75(6 Suppl/):S41-7.

  40. Centers for Disease Control and Prevention. Pelvic Inflammatory Disease – PID. CDC Fact Sheet. Available at http://www.cdc.gov/std/pid/stdfact-pid.htm. Accessed: December 9, 2012.

  41. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012 Dec. 120(6):1314-21. [QxMD MEDLINE Link].

  42. Viberga I, Odlind V, Lazdane G, Kroica J, Berglund L, Olofsson S. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol. 2005 Dec. 13(4):183-90. [QxMD MEDLINE Link]. [Full Text].

  43. Levgur M, Duvivier R. Pelvic inflammatory disease after tubal sterilization: a review. Obstet Gynecol Surv. 2000 Jan. 55(1):41-50. [QxMD MEDLINE Link].

  44. Ness RB, Smith KJ, Chang CC, Schisterman EF, Bass DC. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex Transm Dis. 2006 Mar. 33(3):137-42. [QxMD MEDLINE Link].

  45. Sorbye IK, Jerve F, Staff AC. Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade. Acta Obstet Gynecol Scand. 2005 Mar. 84(3):290-6. [QxMD MEDLINE Link].

  46. World Health Organization. Sexually transmitted infections. Available at http://www.who.int/mediacentre/factsheets/fs110/en/. Accessed: February 2, 2010.

  47. Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. Lancet. 2006 Dec 2. 368(9551):2001-16. [QxMD MEDLINE Link].

  48. Kamwendo F, Forslin L, Bodin L, Danielsson D. Programmes to reduce pelvic inflammatory disease--the Swedish experience. Lancet. 1998. 351 Suppl 3:25-8. [QxMD MEDLINE Link].

  49. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis. 1996 Sep-Oct. 23(5):384-91. [QxMD MEDLINE Link].

  50. Final Recommendation Statement Chlamydia and Gonorrhea: Screening. U.S. Preventive Services Task Force. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/chlamydia-and-gonorrhea-screening. September 2014; Accessed: February 27, 2019.

  51. Banikarim C, Chacko MR. Pelvic inflammatory disease in adolescents. Adolesc Med Clin. 2004 Jun. 15 (2):273-85, viii. [QxMD MEDLINE Link].

  52. Zeger W, Holt K. Gynecologic infections. Emerg Med Clin North Am. 2003 Aug. 21 (3):631-48. [QxMD MEDLINE Link].

  53. Liou TH, Wu CW, Hao WR, Hsu MI, Liu JC, Lin HW. Risk of myocardial infarction in women with pelvic inflammatory disease. Int J Cardiol. 2012 Jan 20. [QxMD MEDLINE Link].

  54. Chen PC, Tseng TC, Hsieh JY, Lin HW. Association between stroke and patients with pelvic inflammatory disease: a nationwide population-based study in Taiwan. Stroke. 2011 Jul. 42(7):2074-6. [QxMD MEDLINE Link].

  55. Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011 Sep. 12(9):900-4. [QxMD MEDLINE Link].

  56. Trabert B, Waterboer T, Idahl A, Brenner N, Brinton LA, Butt J, et al. Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. J Natl Cancer Inst. 2018 May 21. [QxMD MEDLINE Link].

  57. Simms I, Stephenson JM, Mallinson H, Peeling RW, Thomas K, Gokhale R, et al. Risk factors associated with pelvic inflammatory disease. Sex Transm Infect. 2006 Dec. 82(6):452-7. [QxMD MEDLINE Link]. [Full Text].

  58. Toth M, Patton DL, Esquenazi B, Shevchuk M, Thaler H, Divon M. Association between Chlamydia trachomatis and abnormal uterine bleeding. Am J Reprod Immunol. 2007 May. 57(5):361-6. [QxMD MEDLINE Link].

  59. Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001 Apr. 184 (5):856-63; discussion 863-4. [QxMD MEDLINE Link].

  60. Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001 Apr. 184(5):856-63; discussion 863-4. [QxMD MEDLINE Link].

  61. Molander P, Finne P, Sjoberg J, Sellors J, Paavonen J. Observer agreement with laparoscopic diagnosis of pelvic inflammatory disease using photographs. Obstet Gynecol. 2003 May. 101(5 Pt 1):875-80. [QxMD MEDLINE Link].

  62. Risser WL, Risser JM, Benjamins LJ, Feldmann JM. Incidence of Fitz-Hugh-Curtis syndrome in adolescents who have pelvic inflammatory disease. J Pediatr Adolesc Gynecol. 2007 Jun. 20(3):179-80. [QxMD MEDLINE Link].

  63. Sanfilippo JS. The silent epidemic of Chlamydia: what are we missing here?. J Pediatr Adolesc Gynecol. 2008 Oct. 21(5):231-2. [QxMD MEDLINE Link].

  64. Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis. 2007 Apr 1. 44(7):953-60. [QxMD MEDLINE Link].

  65. Tukeva TA, Aronen HJ, Karjalainen PT, Molander P, Paavonen T, Paavonen J. MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US. Radiology. 1999 Jan. 210(1):209-16. [QxMD MEDLINE Link].

  66. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012 Sep. 30(7):1114-7. [QxMD MEDLINE Link].

  67. Schoeman SA, Stewart CM, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ. 2012 Dec 12. 345:e8013. [QxMD MEDLINE Link]. [Full Text].

  68. Taylor-Robinson D, Stacey CM, Jensen JS, Thomas BJ, Munday PE. Further observations, mainly serological, on a cohort of women with or without pelvic inflammatory disease. Int J STD AIDS. 2009 Oct. 20(10):712-8. [QxMD MEDLINE Link].

  69. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol. 2012 Jun. 206 (6):476.e1-8. [QxMD MEDLINE Link].

  70. Thomassin-Naggara I, Darai E, Bazot M. Gynecological pelvic infection: what is the role of imaging?. Diagn Interv Imaging. 2012 Jun. 93(6):491-9. [QxMD MEDLINE Link].

  71. Horrow MM. Ultrasound of pelvic inflammatory disease. Ultrasound Q. 2004 Dec. 20(4):171-9. [QxMD MEDLINE Link].

  72. Goharkhay N, Verma U, Maggiorotto F. Comparison of CT- or ultrasound-guided drainage with concomitant intravenous antibiotics vs. intravenous antibiotics alone in the management of tubo-ovarian abscesses. Ultrasound Obstet Gynecol. 2007 Jan. 29(1):65-9. [QxMD MEDLINE Link].

  73. Del Frate C, Girometti R, Pittino M, et al. Deep retroperitoneal pelvic endometriosis: MR imaging appearance with laparoscopic correlation. Radiographics. 2006. 26(6):1705-18.

  74. Romero R, Espinoza J, Mazor M. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization?. Fertil Steril. 2004 Oct. 82(4):799-804. [QxMD MEDLINE Link].

  75. Liu B, Donovan B, Hocking JS, Knox J, Silver B, Guy R. Improving adherence to guidelines for the diagnosis and management of pelvic inflammatory disease: a systematic review. Infect Dis Obstet Gynecol. 2012. 2012:325108. [QxMD MEDLINE Link]. [Full Text].

  76. Simms I, Vickers MR, Stephenson J, Rogers PA, Nicoll A. National assessment of PID diagnosis, treatment and management in general practice: England and Wales. Int J STD AIDS. 2000 Jul. 11(7):440-4. [QxMD MEDLINE Link].

  77. Shih TY, Gaydos CA, Rothman RE, Hsieh YH. Poor provider adherence to the Centers for Disease Control and Prevention treatment guidelines in US emergency department visits with a diagnosis of pelvic inflammatory disease. Sex Transm Dis. 2011 Apr. 38(4):299-305. [QxMD MEDLINE Link].

  78. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996 May 23. 334(21):1362-6. [QxMD MEDLINE Link].

  79. Trent M, Haggerty CL, Jennings JM, Lee S, Bass DC, Ness R. Adverse adolescent reproductive health outcomes after pelvic inflammatory disease. Arch Pediatr Adolesc Med. 2011 Jan. 165(1):49-54. [QxMD MEDLINE Link].

  80. Anschuetz GL, Asbel L, Spain CV, et al. Association between enhanced screening for Chlamydia trachomatis and Neisseria gonorrhoeae and reductions in sequelae among women. J Adolesc Health. 2012 Jul. 51(1):80-5. [QxMD MEDLINE Link].

  81. US Preventive Services Task Force. Available at . Screening for Chlamydial Infection. Available at http://www.ahrq.gov/clinic/uspstf/uspschlm.htm. Accessed: March 26, 2010.

  82. Gift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis. 2008 Nov. 35(11 Suppl):S66-75. [QxMD MEDLINE Link].

  83. Sexually Transmitted Diseases Treatment Guidelines: Pelvic Inflammatory Disease (PID). Centers for Disease Control and Prevention. Available at https://www.cdc.gov/std/tg2015/pid.htm. June 4, 2015; Accessed: February 27, 2019.

  84. Irwin KL, Moorman AC, O'Sullivan MJ, Sperling R, Koestler ME, Soto I, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000 Apr. 95(4):525-34. [QxMD MEDLINE Link].

  85. Mugo NR, Kiehlbauch JA, Nguti R, Meier A, Gichuhi JW, Stamm WE, et al. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol. 2006 Apr. 107(4):807-12. [QxMD MEDLINE Link].

  86. Trent M, Ellen JM, Walker A. Pelvic inflammatory disease in adolescents: care delivery in pediatric ambulatory settings. Pediatr Emerg Care. 2005 Jul. 21(7):431-6. [QxMD MEDLINE Link].

  87. Ness RB, Soper DE, Holley RL, et al. for the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Study Investigators. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol. 2001. 186:929-37.

  88. Savaris RF, Teixeira LM, Torres TG, Edelweiss MI, Moncada J, Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul. 110(1):53-60. [QxMD MEDLINE Link].

  89. Bakken IJ, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study. BMC Infect Dis. Aug 14 2009. 9(1):130.

  90. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003 Jan-Feb. 31(1):45-54. [QxMD MEDLINE Link].

  91. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One. 2008. 3(11):e3618. [QxMD MEDLINE Link]. [Full Text].

  92. [Guideline] CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006. fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. Apr 13 2007. 56(14):332-6.

  93. [Guideline] Centers for Disease Control and Prevention (CDC). Update to CDC’s Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):. 590-4. [QxMD MEDLINE Link]. [Full Text].

  94. [Guideline] Charvériat A, Fritel X. [Diagnosis of pelvic inflammatory disease: Clinical, paraclinical, imaging and laparoscopy criteria. CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. Gynecol Obstet Fertil Senol. 2019 Mar 13. [QxMD MEDLINE Link].

  95. [Guideline] Cazanave C, de Barbeyrac B. [Pelvic inflammatory diseases: Microbiologic diagnosis - CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. Gynecol Obstet Fertil Senol. 2019 Mar 13. [QxMD MEDLINE Link].

  96. [Guideline] Ah-Kit X, Hoarau L, Graesslin O, Brun JL. [Follow-up and counselling after pelvic inflammatory disease: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. Gynecol Obstet Fertil Senol. 2019 Mar 13. [QxMD MEDLINE Link].

Author

Kristi A Tough DeSapri, MD Clinical Assistant Professor of Obstetrics and Gynecology, Director of Comprehensive Bone Center, University of Chicago Medicine Women's Care

Kristi A Tough DeSapri, MD is a member of the following medical societies: American Society for Colposcopy and Cervical Pathology, North American Menopause Society

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Amgen and AMAG pharmaceuticals.

Coauthor(s)

Monica M Christmas, MD, FACOG, NCMP Assistant Professor, Department of Obstetrics and Gynecology, Section of Minimally Invasive Gynecologic Surgery, Director of Menopause Program, Chief Menopause Editor and Co-Investigator, WomanLab, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

Monica M Christmas, MD, FACOG, NCMP is a member of the following medical societies: American College of Obstetricians and Gynecologists, North American Menopause Society, Society for Academic Specialists in General Obstetrics and Gynecology

Disclosure: Nothing to disclose.

Chief Editor

Acknowledgements

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

What is the best medicine for pelvic inflammatory disease?

Guidelines of the Centers for Disease Control and Prevention recommend outpatient treatment of PID with ofloxacin, levofloxacin, ceftriaxone plus doxycycline, or cefoxitin and probenecid plus doxycycline, all with optional metronidazole for full coverage against anaerobes and bacterial vaginosis (table 1) [13].

What antibiotics treat pelvic inflammatory disease?

Oral therapy usually involves doxycycline; however, azithromycin can also be used. In patients who have developed a TOA, oral therapy should include clindamycin or metronidazole. All patients should be reevaluated in 72 hours for evidence of clinical improvement and compliance with their antibiotic regimen.

How long does it take for pelvic inflammatory disease to clear up?

Treating the Infection To fully treat PID, you may need to take one or more antibiotics. Taking antibiotic medicine will help clear the infection in about 2 weeks.